SecBot SecBot
SECBOTREPLAY Home › Report › DNLI

DNLI · Denali Therapeutics reported Q2 2026 results with AVLAYAH generating…

Denali Therapeutics Inc. · 8-K filed Aug 6, 2026 at 16:03 ET

At the news

MIXEDIMPACT 6/10

8-K filed Aug 6, 2026 at 16:03 ET

Denali Therapeutics reported Q2 2026 results with AVLAYAH generating $3.6M in its first full commercial quarter, beating consensus revenue estimates of $2.2M. EPS of -$0.68 missed consensus of -$0.47 due to commercial build costs and lower interest income. Q3 AVLAYAH revenue guidance of $10-12M signals accelerating uptake, partially offsetting the negative pipeline news of the DNL151 (LRRK2) Phase 2b failure and the DNL593 (FTD-GRN) data delay to 2027.

  • AVLAYAH net product revenue of $3.6M in Q2 2026, first full quarter of launch
  • Q3 2026 AVLAYAH revenue guidance of $10.0M to $12.0M
  • EPS of -$0.68 vs consensus -$0.47 (miss of 44.7%)
  • Net loss of $127.6M vs $124.1M in Q2 2025

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access